introduction
Advancements in integrated chemo-and radiotherapy over the last four decades have made Hodgkin lymphoma (HL) a largely curable disease, and its mortality rates had declined by >75% in the United States, western Europe and Japan between the early 1960s and the late 1990s [1] . However, in former nonmarket economy countries in central and eastern Europe, the fall in rates was much smaller up to the late 1990s when mortality from HL was over two-fold higher in those countries compared with western Europe or the United States [1, 2] .
To update trends in mortality from HL in various areas of Europe, we have now considered HL mortality rates up to 2004. We have also contrasted trends in incidence with those in mortality for the 11 countries providing national data on both incidence and mortality.
materials and methods
Official death certification data from HL for 26 European countries for the period 1980-2004 were derived from the World Health Organization (WHO) database available on electronic support [3] . The European Union (EU 27) was defined as the 27 member states as since January 2007 (i.e. Austria, Bulgaria, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK), with the exclusion of Cyprus (data not available), Belgium and Latvia (data available only for a limited number of years). The 15 countries of the EU from western and northern Europe as before May 2004 with the exclusion of Belgium (EU 15, i.e. Austria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Spain, Sweden, UK) and the 10 central and eastern accession countries in 2004 and 2007 with the exclusion of Latvia (EU 10, i.e., Bulgaria, the Czech Republic, Estonia, Hungary, Lithuania, Poland, Romania, Slovakia, and Slovenia) were also considered separately.
In the two decades considered, three different Revisions of the International classification of diseases (ICD) were used [4] [5] [6] . There were, however, no differences in coding and classification of HL across the three ICD Revisions.
Estimates of the resident population, based on official censuses, were obtained from the same WHO database [3] . From the matrices of certified deaths and resident populations, age-specific rates for each 5-year age group and calendar period were computed. Age-standardized rates per 100 000, at original article all ages and in various age groups, were computed using the direct method, based on the world standard population [7] . In a few countries, data were missing for part of one or more calendar years. No extrapolation was made for missing data. Incidence data for 11 European countries providing national data were extracted from the successive volumes of Cancer Incidence in Five Continents [8] . Additional more recent information was found in various national cancer registry reports available in Internet [9] [10] [11] [12] [13] [14] [15] [16] .
results Table 1 shows the age-adjusted death rates from HL per 100 000 men and women in selected European countries in 1980-1984, 1990-1994 and 2000-2004 , and the corresponding changes in rates. In most western European countries, mortality from HL continued to steadily decline in the last two decades. In proportional terms, the falls were similar in the two subsequent decades, although in absolute terms these were smaller over more recent calendar years. In Bulgaria, Hungary and Romania, HL mortality was still increasing between 1980-1984 and 1990-1994 (Figure 1) .
The pattern of trends in young adults (aged 20-44 years) across most European countries was similar to that of all ages Table 1 . Overall age-standardized (world population) mortality rates from Hodgkin lymphoma per 100 000 men and women in selected European countries in [1980] [1981] [1982] [1983] [1984] [1990] [1991] [1992] [1993] [1994] (Table 2 ). However, in Poland and Romania, decreasing trends were already observed between 1980-1984 and 1990-1994 . The different pattern in overall mortality from HL in the EU 27, EU 15 and EU 10 is showed in Figure 2 . Mortality steadily declined in the EU 27 and EU 15 throughout the period 1980-2004, while in the EU 10 comparable reductions were observed only after the mid 1990s. Table 3 shows the age-standardized mortality rate from HL per 100 000 men and women from the EU 27, the EU 15 and EU 10, in four age groups in the years 1980-1984, 1990-1994 and 2000-2004. In the EU 27 and EU 15, the reductions in HL mortality between 1980-1984 and 1990-1994 were larger in the youngest age groups than in elderly population, while this gradient with age was less evident over recent calendar years. Similarly, in the EU 10 between 1980-1984 and 1990-1994, mortality started to decline first in the younger age group, while upward trends were observed in population aged 65 or more. Reductions similar to those observed in the EU 15 between 1980-1984 and 1990-1994 were observed in the EU 10 between 2000-2004 and 1990-1994. Table 4 shows the age-standardized incidence rates from HL in 11 European countries. Incidence in men showed no consistent pattern across countries, with slight downward trends, particularly in the last decade, in men from the Czech Republic, Denmark, Ireland, Slovakia, Sweden and Scotland and upward trends in The Netherlands and Norway. No consistent patterns in incidence were observed in women too, and if anything, slight upward trends were observed.
Figures 3 and 4 contrast trends in age-adjusted mortality and incidence rates from HL in men and women from 11 European countries providing also incidence data. Mortality consistently decreased in all countries considered, although in most countries mainly from northern Europe the decline tended to slow down in most recent years. The pattern of HL incidence was less clear, with no consistent trends in various calendar years, across the countries examined and between sexes.
discussion
The present report shows that the decline in the mortality from HL observed in western and northern Europe since the 1960s has continued over more recent calendar years [1] . More important, over the last years, HL mortality has started to decline also in the EU 10 accession countries from central and eastern Europe, which were characterized by unfavorable trends up to the 1990s. The mortality rates of the EU 10 countries in original article Annals of Oncology the early 2000s were, however, still higher than those of the EU 15 ones and were comparable to those observed in the EU 15 countries almost a decade earlier.
HL incidence showed no consistent patterns, with stable or slightly downward trends in men and less favorable ones in women [17, 18] . This indicates that no important new causes of HL have been introduced on population level over the last few decades.
The dynamic and evolving classification of lymphomas and the consequent changes in HL registration may have had some contribution in temporal trends [19, 20] . However, the absence of appreciable changes in incidence suggests that they are unlikely to appreciably account for such generalized favorable trend in HL mortality observed in European countries, as well as other areas of the world.
The persistence of favorable trends in HL mortality in countries from western and northern Europe indicates, therefore, that advancements in diagnosis and treatment for these neoplasms-with a consequent favorable impact on survival [17, 18] -are still in course. During the past two decades, staging by means of laparotomy and splenectomy has been abandoned, and new and better methods have been introduced, including the use of a more sensitive metabolic imaging technique, the positron emission tomography with 18 F-fluorodeoxyglucose as a tracer [21, 22] . Treatment of the disease has also improved, through advancements in combined radiotherapy and chemotherapy. Moreover, prognostic factors have been identified which impact survival and may help tailoring the treatments [23] [24] [25] . More important, the recent favorable patterns in central and eastern Europe indicate that-after substantial delays-progresses in the treatment of HL have also been made in those countries. However, the persistence of higher rates in eastern as compared with western European countries indicates that there is still scope for advancements in HL control and treatment in those countries, simply by widespread adoption of available and up to date medical treatment and/or radiotherapy. As for other lymphoid original article Annals of Oncology neoplasms [26] , this has to be extended in middle-aged and elderly individuals, too, since the difference in mortality between western and central/eastern European countries is greater in those age groups.
Thus, the present work confirms the persistent favorable trends in HL mortality in western European countries and indicates recent improvements in central/eastern European countries, though the gap in HL mortality across various areas of Europe is still considerable and calls for urgent interventions to control this largely avoidable cause of death. 
